Download PDF
Exp Clin Endocrinol Diabetes 1987; 89(3): 301-306
DOI: 10.1055/s-0029-1210654
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes

A. Signore1 , 3 , P. C. L. Beverley1 , A. Parman2 , M. Negri3 , P. Pozzilli2 , 3
  • 1ICRF, HTIG, Faculty of Clinical Sciences, University College London
  • 2Department of Diabetes and Immunogenetics, St. Bartholomew's Hospital, London/UK
  • 3Cattedra Endocrinologia I, Clinica Medica II, University of Rome “La Sapienza”/ Italy
Further Information

Publication History

1986

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Human recombinant interleukin-2 (IL-2) was labelled with Iodine-123 using modified Bolton and Hunter method. Separation from free iodine was performed by gel filtration chromatography using a Sephadex G10 column. HPLC analysis of labelled IL-2 showed that 98% of TCA precipitable radioactivity eluted in a single peak.

The immunoreactivity of 123I-labelled IL-2 was determined by divert binding using the Fluorescence Activated Cell Sorter (FACS) and by receptor binding assay of IL-2 to activated lymphocytes.

To demonstrate in vivo binding to activated lymphocytes, 123I-labelled IL-2 was injected intravenously into a newly diagnosed diabetic BB/Wistar rat. Higher radioactivity was detected in the pancreas and in the lymph nodes of the BB/W rat compared to a normal rat.

These preliminary data show that 123I-labelled IL-2 retains its immunoreactivity and capacity to bind to activated lymphocytes both in vitro and in vivo and may be used for in vivo localization of lymphocytic infiltration in Type 1 diabetes.

Key words

Interleukin-2 - Activated lymphocytes - BB/Wistar rat - Type 1 diabetes